Member Info for Energyshares

Ten Bob Tony won 7/1 at Newmarket today

Bloody hell 50p Tony Gardiner 😂😂

Pre|CISION+

Just came out the blue or have they working on this for a while, is this the reason Smith said “ funding don’t worry about that”

As soon as this patent is approved we could see some action in SP.

That haven’t commercialised Pre/Cision

But have now moved onto Pre/Cision +

I have a feeling there is a Major announcement coming very soon…

The Avacta pre|CISION+ platform is based on the peptide drug conjugate delivery model which is then conjugated to a biologic protein moiety such as the Fc region of an antibody or AffimerXT® to significantly extend the half-life and optimise the pharmacokinetics of the peptide drug conjugate.

Significant extension of the half-life of the pre|CISIONTM warhead will benefit certain warheads that target tumours differently from traditional cytotoxics. Examples of such pre|CISION+ warheads include cancer pathway targeted therapies or immune modulators where more consistent and concentrated delivery to the TME is optimal.

WET Cancer go away

Has any company ever presented chemo results to the FDA with so little side effects.

Would it not be ethical that the FDA approve as quick as possible.

These results must set a precedent on the grounds of safety even if showing just the efficacy shown so far.

Why would LG Chem,Daewoong and Eli Lilly

All pay $180m LG Chem,

Daewoong give 25% of Affxell,

Eli Lilly pay licence fee on Point Bio deal.

When any of them only has to offer a cheeky T/O price now to test PI’s patience.

II’s still the minority in this company.

At £180m MCap, Smith & Gardiner and the board have put Avacta on a very dangerous position.

LG Chem

This multi-target therapeutics development agreement provides for upfront and near-term milestone payments, plus longer-term clinical development milestones totalling $180million.

Daewoong

The second milestone will result in an increase in Avacta's shareholding in AffyXell, which currently stands at 19%. The exact shareholding will be determined, as with the first milestone payment which was achieved in April 2022, following a formal valuation of AffyXell.

Our presentation at #AACR24 today - well received with many intriguing conversations.

Grateful and humbled by our lead author Prof @udai_banerji who did not stop speaking for 3.5 hours. Udai - much appreciated

#PeptidesCreateHope

#LetsDoThis

Https://consilium-comms.com/news-insights/icr-consilium-conscience/icr-consilium-conscience/2024/the-inside-track-on-aacr-from-dr-christina-coughlin-head-of-rd-avacta/

Cancer medications granted accelerated approval are often confirmed despite not demonstrating a benefit in overall survival or quality of life.

In a separate analysis, researchers looked at the reasons why drugs granted accelerated approval between 2013 and 2023 were converted to regular approval. They found that 40% were based on how long people survived, the gold standard for cancer medicines. Another 44% were based on how long people went without their cancer growing; 10% were based on finding that tumors shrank, called response rate, and the duration of that response; and 4% were based on response rate alone. One drug received regular approval despite a confirmatory trial that found no difference in overall survival or time to cancer recurrence between patients receiving the new treatment and those getting the existing standard of care.

Reading this with data Avacta has stated it’s hard not to see AVA6000 approved…..

https://www.cancertodaymag.org/cancer-talk/results-that-matter/?utm_medium=twitter&utm_source=social&sf187596192=1

Gardener working on his abacus now with his Dick Turpin mask on working out how many more free shares he should award to himself and Smith.

Avacta present their poster on day 5 of the AACR Conference.

Simon Bennett Chief Business Officer will have had 4 full days of meetings with BP before the poster,could we get a LD announced next week…

Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.

RNS. 5 April 2023

 

Avacta Group plc

 

("Avacta" and, together with its subsidiary undertakings, the "Group")

 

First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study

All patients still on drug

RAH twitter

That’s 12 months on drug….WOW

Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.

How many meetings has Simon scheduled

Sadly just a rehash of December data as I expected but not what I hoped for. Oh well roll on the webinar.

Touk you are a P. Rick

AVA6000 doses from 80mg/m2 (51 mg/m2 doxorubicin; molar equivalent, 0.675) to 385 mg/m2 (260 mg/m2 doxorubicin equivalent).

No grade 4 non-hematologic toxicities were reported.

That’s should be enough for approval.

Everyone just ignore and report the trolls.

Right all the news we have had about the trial the one piece of news that turned my head was :

Nurses couldn’t tell if patients had been dosed with Chemo

Let that sink in:

These nurses are seeing cancer patients daily watching them deteriorate physically and mentally watching cancer & chemo slowly killing them.

Yet with Ava6000 they couldn’t tell if they were on chemo:

Roll on the 9th & 10th (Holy Grail) results

B2H

I’m not asking for price sensitive info

Just Communication.

Need to start boosting why sit in radio silence keeping investors guessing with SP trashed and Trolls and city shorters in control.

Avacta has Major news on its AVA6000 P1 trial results in a weeks time.

Where is the Communication department are they in the same Bunker as Smith & Gardiner.

Why throw all eggs at one Investor presentation where SP reaction could go 50/50

Start communicating with Media Let CC’s R&D department start to release more clips.

Come on Avacta get a grip start to repair LTH’s trust.

To deliver first-in-class cancer therapies that boost efficacy and minimise off target toxicity.

So not just improve efficacy but boost it.

About time started Boosting

KEY POINTS

A patient selection strategy is essential to rapid drug approval.

Expansion phases of phase I trials allow early establishment of disease response rates.

Biomarkers for patient selection can be validated in expanded phase I.

One confirmatory phase II may be sufficient for accelerated approval.

Postapproval trials may refine the dose, schedule, sequence, and combination therapies.

https://ascopubs.org/doi/10.14694/EdBook_AM.2012.32.114